Capricor Therapeutics $CAPR announced the completion of Phase 2 enrollment for clinical trial, ALLSTAR, which is assessing CAP-1002 (allogeneic cardiosphere-derived cells, or CDCs) in adults with cardiac dysfunction following a large heart attack (myocardial infarction, or MI). The randomized, double-blind, placebo-controlled clinical trial has enrolled adults with a history of MI within the prior 12 months that resulted in scar tissue replacing at least 15% of total left ventricular mass. The primary endpoint is infarc size as measured by MRI. ALLSTAR will also explore additional efficacy parameters, such as ejection fraction and cardiac volumes, as well as evaluate the safety and tolerability of CAP-1002. The expected clinical trial completion date is September 2021.